Head-to-head trial dents Novo Nordisk's obesity hopes Novo Nordisk slumps as its two-drug combination for weight loss, CagriSema, performs less well than Eli Lilly's rival Zepbound in a comparative trial.

#NovoNordisk's new two-drug combination for #weightloss, #CagriSema, performed worse than Eli Lilly's rival Zepbound in a #comparativetrial, putting further pressure on its stock.